Savara Inc. (SVRA) — Research Summary as of August 19, 2026

Company Overview

Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases, headquartered in Langhorne, Pennsylvania [2][24]. The company's sole clinical asset is molgramostim inhalation solution (branded MOLBREEVI), an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) — a rare, chronic lung disease with no currently FDA-approved therapies [18][20][24]. Savara is a small-cap company with a market capitalization between $300 million and $2 billion [30].

---

Key Recent Catalysts (Last ~1–3 Months)